194 related articles for article (PubMed ID: 12652358)
1. Rationale and options for combination therapy in the treatment of Type 2 diabetes.
Van Gaal LF; De Leeuw IH
Diabetologia; 2003 Mar; 46 Suppl 1():M44-50. PubMed ID: 12652358
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
5. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
6. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.
Standl E; Füchtenbusch M
Diabetologia; 2003 Mar; 46 Suppl 1():M30-6. PubMed ID: 12652356
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
8. Recent developments and emerging therapies for type 2 diabetes mellitus.
Evans AJ; Krentz AJ
Drugs R D; 1999 Aug; 2(2):75-94. PubMed ID: 10820647
[TBL] [Abstract][Full Text] [Related]
9. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
Giugliano D; Ceriello A; Razzoli E; Esposito K
Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
[TBL] [Abstract][Full Text] [Related]
11. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
12. [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Hanefeld M; Fischer S
MMW Fortschr Med; 2003 Feb; 145(9):30-4. PubMed ID: 12666526
[TBL] [Abstract][Full Text] [Related]
13. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Acta Clin Belg; 1993; 48(4):259-68. PubMed ID: 8212978
[TBL] [Abstract][Full Text] [Related]
14. Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
Lebovitz HE
Drugs; 1992; 44 Suppl 3():21-8. PubMed ID: 1280574
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
16. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Füchtenbusch M; Standl E; Schatz H
Exp Clin Endocrinol Diabetes; 2000; 108(3):151-63. PubMed ID: 10926309
[TBL] [Abstract][Full Text] [Related]
19. Effects of current therapeutic interventions on insulin resistance.
Kobayashi M
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S32-40. PubMed ID: 11220286
[TBL] [Abstract][Full Text] [Related]
20. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
